We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




MicroRNA Blocks Proapoptotic Genes in Mature Nerve Cells

By LabMedica International staff writers
Posted on 08 Feb 2011
A microRNA (miRNA) has been identified that blocks the activity of proapoptotic proteins in mature nerve cells and may be a potential drug for the treatment of neurodegenerative disorders.

During development, nerve cells that fail to connect to target tissues self-destruct. More...
Yet, once such connections are made, surviving neurons become resistant to apoptosis for the life span of the organism.

Investigators at the University of North Carolina (Chapel Hill, USA) studied the mechanism underlying this radical change in behavior. They considered the class of gene-regulating molecules known as microRNAs to be a particularly promising target. To this end, they screened all known miRNAs to identify differences between immature and mature neurons.

Results published in the January 15, 2011, online edition of the journal Genes & Development revealed that the microRNA miR-29 was markedly induced with neuronal maturation. Immature neurons that would normally die became resistant to apoptosis following exposure to miR-29. Furthermore, analysis of brain tissues from patients with Alzheimer's disease or Huntington's disease showed reduced levels of miR-29.

The investigators reported that at the molecular level miR-29 blocked the activity of the genes that encode the BH3-only proapoptotic protein family. MiR-29 was able to inhibit several of these genes, circumventing a redundancy that allowed apoptosis to continue even if one of them had been blocked.

"There is the real possibility that this molecule could be used to block the cascade of events known as apoptosis that eventually causes brain cells to break down and die,” said senior author Dr. Mohanish Deshmukh, associate professor of cell and developmental biology at the University of North Carolina.

"People in the field have been perplexed that when they have knocked-out any one of these members it has not had a remarkable effect on apoptosis because there are others that can step in and do the job,” said Dr. Deshmukh. "The fact that this microRNA can target multiple members of this family is very interesting because it shows how a single molecule can basically in one stroke keep apoptosis from happening. Interestingly, it only targets the members that are important for neuronal apoptosis, so it may be a way of specifically preserving cells in the brain without allowing them to grow out of control (and cause cancer) elsewhere in the body.”

Related Links:
University of North Carolina


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.